20-F: OKYO Pharma Reports FY26 Results, Focuses on Urcosimod

OKYO Pharma Limited filed its Form 20-F for the fiscal year ended March 31, 2026, detailing its ongoing development of urcosimod for neuropathic corneal pain and its financial performance.

Summary

• OKYO Pharma Limited filed its annual report on Form 20-F for the fiscal year ended March 31, 2026.
• The company is focused on developing urcosimod, a potential first-in-class treatment for neuropathic corneal pain (NCP).
• The Phase 2 trial for urcosimod in NCP patients was stopped early due to compelling pain relief data, with 75% of patients in the 0.05% urcosimod group showing over 80% improvement in pain severity.
• New analyses suggest urcosimod may also positively impact corneal nerve health.
• The company appointed Robert J. Dempsey as CEO and Flavio Mantelli as CMO, strengthening its leadership team.
• OKYO Pharma raised approximately $20 million in an underwritten public offering in February 2026 to fund its Phase 3 trial and working capital.
• The company reported a net loss of $8.95 million for the fiscal year ended March 31, 2026, compared to a net loss of $4.71 million in the prior year.
• R&D expenses decreased to $1.81 million from $2.25 million in the prior year, primarily due to the settlement of patent invoices.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with positive clinical trial signals for urcosimod and strong leadership appointments, but tempered by continued net losses and the need for significant future funding.

Positives

• Successful Type C and Type D meetings with the FDA regarding urcosimod's development for NCP, confirming the clinical meaningfulness of the primary endpoint (VAS pain reduction) and endorsing the Phase 3 study design.
• Fast Track designation granted by the FDA for urcosimod for the treatment of NCP, facilitating development and expediting review.
• Positive results from the Phase 2 trial of urcosimod in NCP patients, showing a marked reduction in pain scores and a strong treatment effect size.
• Exploratory analysis of corneal images from the Phase 2 NCP trial indicated potential positive impacts of urcosimod on corneal nerve health.
• Appointment of experienced leadership with Robert J. Dempsey as CEO and Flavio Mantelli as CMO.
• Successful completion of a public offering in February 2026, raising approximately $20 million to fund further development.
• Urcosimod demonstrated stability for over two and a half years in single-use ampoules.
• The company has a strong intellectual property portfolio with multiple issued patents and pending applications.

Negatives

• The company incurred a net loss of $8.95 million for the fiscal year ended March 31, 2026, and has a history of net losses.
• The Phase 2 trial for urcosimod in NCP was stopped early with only 18 patients completing the study, meaning the statistical significance for the primary endpoint was not met in the per-protocol population (p=0.07).
• The intent-to-treat population analysis did not meet the threshold for statistical significance (p=0.2).
• The company will require substantial additional capital to fund its ongoing operations and product development.
• The company has no revenue from product sales and does not expect to generate any in the near future.
• General and administrative expenses increased by $1.85 million due to option charges, legal expenses, recruitment, and public relations.
• The company's cash and cash equivalents were $20.6 million as of March 31, 2026, which may not be sufficient to fund all planned activities.
• The company is dependent on third-party manufacturers and service providers, which introduces risks.

Risks

• Product candidates are in early to mid-stage development, and revenue generation is not expected for several years, if at all.
• High failure rate for product candidates in clinical trials, with data subject to varying interpretations.
• Inability to obtain or maintain regulatory approval for product candidates.
• Failure to raise substantial additional capital when needed, which could force delays or elimination of development programs.
• Inability to successfully commercialize products even if regulatory approval is obtained.
• Significant competition from established pharmaceutical companies with greater resources.
• Dependence on third-party supply, development, and manufacturing, and potential issues with these relationships.
• Potential for intellectual property challenges, including patent infringement claims or inability to enforce proprietary rights.

Future Outlook

The company anticipates increased R&D expenses as it advances its product candidates, particularly for the upcoming Phase 3 trial for urcosimod. It expects to continue incurring losses and will likely need to raise additional capital to fund its operations and development activities.

Management Comments

• Robert J. Dempsey, CEO, brings over two decades of global ophthalmology experience, including drug development and commercialization.
• Flavio Mantelli, CMO, has extensive experience in ocular surface drug development, including the successful launch of Oxervate.
• Gabriele Cerrone, Non-Executive Chairman, has founded multiple biotechnology companies and achieved several FDA drug product approvals.

Industry Context

StockSavvy.ai notes that OKYO Pharma operates in the highly competitive ophthalmology sector, focusing on unmet needs in corneal and anterior segment diseases. The company's lead candidate, urcosimod, targets neuropathic corneal pain, a condition with no current FDA-approved therapies, positioning it to address a significant market gap.

Management Changes

Related Party Transactions

• Shared services agreement with Tiziana Life Sciences Ltd.
• Short-term credit facilities provided by Tiziana Life Sciences Ltd. which were converted into shares.
• Loan agreements with existing shareholders that were converted into shares.
• Fees owed to directors for services rendered.

Stakeholder Impact

• Shareholders may experience dilution if additional equity is issued to fund operations.
• Investors will be closely watching the progress of the urcosimod Phase 3 trial for potential future value creation.
• The company's ability to secure future funding will impact its operational capacity and long-term prospects.

Next Steps

• Advance urcosimod into a Phase 3 global clinical trial for neuropathic corneal pain.
• Continue to manage working capital and explore further financing options.
• Focus on regulatory interactions with the FDA for urcosimod's development pathway.
• Potentially explore further development of OK-201 if resources allow.

Key Dates

Recommendation

The company shows promising clinical data for its lead drug candidate, urcosimod, and has secured key leadership appointments and funding. However, the increased net loss, the early termination of the Phase 2 trial without achieving statistical significance in all analyses, and the ongoing need for substantial capital present significant risks. A 'hold' recommendation reflects the potential upside from successful clinical development balanced against the considerable execution and financial risks.

Keywords

OKYO Pharma, Urcosimod, Neuropathic Corneal Pain, Ophthalmology, Clinical Trials, FDA, Biotechnology, Drug Development